Strensiq
NICE agrees approval deal for ultra-rare juvenile bone disease
July 5, 2017Research and Development, Sales and Marketing Alexion, NICE, Strensiq
NICE has announced that it has decided to approve Alexion Pharma’s Strensiq (asfotase alfa) for the treatment of ultra-rare disease …
Alexion hits out at NICE ruling on Strensiq
February 8, 2017Research and Development, Sales and Marketing Alexion, NICE, Strensiq
NICE has again drawn the ire of a company over its recommendation of its drug, this time round it’s Alexion …
NICE approval for restricted-use hypophosphatasia therapy
September 23, 2016Medical Communications, Sales and Marketing Alexion Pharmaceuticals, Strensiq, hypophosphatasia
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Alexion Pharmaceutical’s Strensiq …
NICE turns down bone disorder drug for NHS
December 3, 2015Research and Development Alexion, NICE, Strensiq
NICE has published draft guidance as part of its highly specialised technologies programme, not recommending Alexion Pharma’s Strensiq (asfotase alfa) …
Alexion scores double EU approval
September 1, 2015Manufacturing and Production, Sales and Marketing Alexion, EC, European Commission, Kanuma, Strensiq, asfotase alfa, sebelipase alfa, ultra rare disease, ultra-rare disease
Two treatments developed by ultra-rare disease specialists Alexion Pharmaceuticals are now approved for use in Europe. The European Commission approved …
